loading
Viridian Therapeutics Inc stock is traded at $13.80, with a volume of 525.26K. It is up +5.37% in the last 24 hours and down -9.34% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$13.13
Open:
$13.34
24h Volume:
525.26K
Relative Volume:
0.56
Market Cap:
$1.04B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.247
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
+8.09%
1M Performance:
-9.34%
6M Performance:
-43.39%
1Y Performance:
-3.25%
1-Day Range:
Value
$13.25
$13.87
1-Week Range:
Value
$12.27
$13.87
52-Week Range:
Value
$9.90
$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name
Name
Viridian Therapeutics Inc
Name
Phone
617.272.4600
Name
Address
221 CRESCENT STREET, WALTHAM
Name
Employee
143
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VRDN's Discussions on Twitter

Compare VRDN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRDN
Viridian Therapeutics Inc
13.80 1.04B 288.00K -228.06M -168.82M -4.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.62 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.71 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.69 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.00 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.42 26.16B 3.81B -644.79M -669.77M -6.24

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Nov-25-24 Initiated TD Cowen Buy
Sep-11-24 Reiterated Needham Buy
Jun-11-24 Initiated Wolfe Research Outperform
Jun-06-24 Initiated Goldman Buy
May-09-24 Downgrade B. Riley Securities Buy → Neutral
May-09-24 Downgrade Ladenburg Thalmann Buy → Neutral
Jun-14-23 Initiated BTIG Research Buy
Jun-14-23 Resumed Credit Suisse Outperform
May-30-23 Initiated RBC Capital Mkts Outperform
Apr-17-23 Initiated Wells Fargo Overweight
Mar-30-23 Initiated Stifel Buy
Dec-19-22 Initiated Cowen Outperform
Dec-19-22 Initiated Needham Buy
Dec-16-22 Initiated Credit Suisse Outperform
Dec-01-22 Initiated H.C. Wainwright Buy
Jun-23-22 Initiated B. Riley Securities Buy
Nov-18-21 Initiated SVB Leerink Outperform
Oct-12-21 Initiated Evercore ISI Outperform
Jan-25-21 Initiated Ladenburg Thalmann Buy
View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

pulisher
Apr 18, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Geode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com

Apr 15, 2025
pulisher
Apr 11, 2025

Sector Update: Health Care - TradingView

Apr 11, 2025
pulisher
Apr 11, 2025

Graves Ophthalmopathy Therapeutics Market Size in 7MM - openPR.com

Apr 11, 2025
pulisher
Apr 10, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Lifted by Vanguard Group Inc. - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

American Century Companies Inc. Has $2.18 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

KLP Kapitalforvaltning AS Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - BioSpace

Apr 07, 2025
pulisher
Apr 07, 2025

Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Viridian Therapeutics appoints Jeff Ajer to board - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Viridian Therapeutics appoints Jeff Ajer to board By Investing.com - Investing.com UK

Apr 07, 2025
pulisher
Apr 07, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Corebridge Financial Inc. - Defense World

Apr 07, 2025
pulisher
Apr 04, 2025

Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 03, 2025

(VRDN) Trading Report - news.stocktradersdaily.com

Apr 03, 2025
pulisher
Apr 02, 2025

Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World

Mar 15, 2025
pulisher
Mar 12, 2025

Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation - Investing.com India

Mar 10, 2025
pulisher
Mar 06, 2025

What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

How to Take Advantage of moves in (VRDN) - Stock Traders Daily

Mar 02, 2025

Viridian Therapeutics Inc Stock (VRDN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Viridian Therapeutics Inc Stock (VRDN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mahoney Stephen F.
President and CEO
Sep 27 '24
Buy
23.33
21,400
499,262
21,400
Fairmount Funds Management LLC
Director
Sep 13 '24
Buy
18.75
1,600,000
30,000,000
3,445,813
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):